세계의 저분자 CMO 시장 규모 : 용도별, 지역별, 범위 및 예측

Small Molecule CMO Market Size And Forecast

Small Molecule CMO Market size was valued at USD 47.8 Billion in 2024 and is projected to reach USD 84.0 Billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031. The growing pharmaceutical industry and rising demand for oncology drugs are the major factors that are driving the growth of the market. The Global Small Molecule CMO Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Small Molecule CMO Market Definition

CMO states contract manufacturing organization. CMO is also called contract development and manufacturing organization (CDMO). It is an organization that serves other companies in the pharmaceutical industry on a contract basis to make available comprehensive services from drug development through drug manufacturing. completion of projects and subsequent regulatory submission. Small molecules are primarily made up of naturally occurring compounds that have been isolated or re-synthesized in the laboratory. These are interchangeably called drugs. The majority of drugs have come under the category of small molecules. Small molecules are well defined and independent of the manufacturing process.

The industry has been alternating between the cycles of inadequate and excessive production capacity for the contract as well as captive manufacturers. Hence, it is important for Contract Manufacturing Organizations (CMOs) to make cautious decisions pertaining to capacity expansion and choice of deals. One-stop-shop" offered by the CMO's for the promotion of a portfolio of a complete range of products is anticipated to influence the growth of CMO's. The larger CMOs are embracing the trend of moving and focusing on the niche areas of biopharmaceutical and pharmaceutical development. They are focusing on the establishment of regulatory pathways for transgenic-based product development.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Small Molecule CMO Market Overview

The growing pharmaceutical industry and rising demand for oncology drugs are the major factors that are driving the growth of the market. Other growth drivers such as growing demand for process development CMO services, robust pipeline of small molecule drugs & increasing rate of FDA approvals, mergers & acquisitions, growing demand for CDMOs offering highly potent API etc. are expected to boost the growth of the market in the near future.

In addition, Cost saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving industrial growth. Companies are investing in infrastructure, personnel, and technology in order to gain a significant share of the outsourcing revenue. Increasing demand as a consequence of the ongoing patent cliff of the biologic drugs is expected to fuel demand. Furthermore, the Presence of end-to-end service providers that are engaged in providing value-added services for an integrated or risk-sharing business model is expected to bolster progress in this industry.

Moreover, new product launches and novel drug delivery mechanisms are anticipated to drive outsourcing demand. The industry has been alternating between the cycles of inadequate and excessive production capacity for the contract as well as captive manufacturers. Hence, it is important for Contract Manufacturing Organizations (CMOs) to make cautious decisions pertaining to capacity expansion and choice of deals.

However, there are several challenges and complications allied with the present business model of CMOs globally. The fragmented nature of the market combined with price pressure, lower unit volumes and new technologies and lack of Venture Capitalist (VC) funding for early-stage companies have resulted in less expenditure than precession levels which is likely to pose a threat to CMOs.

Global Small Molecule CMO Market: Segmentation Analysis

The Global Small Molecule CMO Market is Segmented on the basis of Application, and Geography.

Small Molecule CMO Market, By Application

• Cardiovascular
• Oncology
• Diabetes
• Immunological Disorders
• Based on Application, the market is bifurcated into Cardiovascular, Oncology, Diabetes, and Immunological Disorders. Immunological Disorders are likely to register the highest CAGR over the forecast period. API dominated with respect to revenue as a consequence of the rising demand for
• High Potency Active Pharmaceutical Ingredients (HPAPI)
• . Market entities are engaged in the development of large-scale mfg. facilities on the pilot as well as commercial scale.

Small Molecule CMO Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World
• On the basis of regional analysis, The Global Small Molecule CMO Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominated with respect to revenue share in 2016, however, Asia Pacific is projected to grow at a surplus rate. This growth is supported by rising in the number of companies outsourcing projects in the developing economies of this region. A larger share of the North American region is a consequence of the expansion of the U.S. healthcare industry. This share is anticipated to decrease to a substantial extent thus driving the share of BRIC countries in this sector

Key Players

• The "Global Small Molecule CMO Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as
• Lonza Group, Wuxi AppTec Co. Ltd., Catalent Inc, Patheon Inc., Cambrex, SIEGFRID, WuXi Biologics, Groupe PCAS.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Partnerships, Collaborations and Agreements
• On July 2020, Viatris extended its partnership with Gilead to build COVID-19 treatments by announcing a global agreement with the company to commercial Remdesivir in 127 low- and middle-income countries. The drug was launched under the brand name DESREM in India. Viatris has a long-standing history of partnering with Gilead Sciences to tackle critical public health issues in India and worldwide, beginning with expanding access to high-quality, affordable HIV/AIDS antiretrovirals.
• On June 2021, Eisai Co., Ltd. and Bristol-Myers Squibb Company announced a global strategic partnership agreement to develop and commercialize MORAb-202, an antibody-drug combination. MORAb-202 will be developed and commercialized jointly by Eisai and Bristol Myers Squibb under the terms of the agreement. Eisai would remain responsible for the manufacturing and supply of MORAb-202 globally.
• On August 2021, Cipla Limited and Kemwell Biopharma Private Limited, a biopharmaceutical Contract Development and Manufacturing Organization announced a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets. Under the terms of the agreement, the joint venture would leverage Cipla and Kemwell's complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing, and commercialization of biopharmaceutical products.
• Mergers and Acquisitions
• On July 2020, US-based Advent International agreed to acquire a controlling stake in RA Chem Pharma from its parent Micro Labs. Another US-based giant, KKR, also agreed to acquire a 54% stake in JB Chemicals and Pharmaceuticals for USD 611 million.
• Product Launches and Product Expansions
• On December 2020, Viatris sponsored the Panacea event in India and Narayana Health, Ayush Society, to improve focus on mental health improvement in India. It conducts a series of virtual sessions on yoga, stress management, nutrition, and mental health to help patients overcome post-COVID-19 anxiety, fear, and mental trauma. Special sessions were conducted by renowned pulmonologists, neurologists, and cardiologists.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL SMALL MOLECULE CMO MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL SMALL MOLECULE CMO MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model
• 4.4. Value Chain Analysis

5. GLOBAL SMALL MOLECULE CMO MARKET, BY APPLICATION

• 5.1. Overview
• 5.2. Cardiovascular
• 5.3. Oncology
• 5.4. Diabetes
• 5.5. Immunological Disorders

6. GLOBAL SMALL MOLECULE CMO MARKET, BY GEOGRAPHY

• 6.1. Overview
• 6.2. North America
  • 6.2.1. U.S.
  • 6.2.2. Canada
  • 6.2.3. Mexico
• 6.3. Europe
  • 6.3.1. Germany
  • 6.3.2. U.K.
  • 6.3.3. France
  • 6.3.4. Rest of Europe
• 6.4. Asia Pacific
  • 6.4.1. China
  • 6.4.2. Japan
  • 6.4.3. India
  • 6.4.4. Rest of Asia Pacific
• 6.5 Rest of the World
  • 6.5.1 Latin America
  • 6.5.2 Middle East & Africa

7. GLOBAL SMALL MOLECULE CMO MARKET COMPETITIVE LANDSCAPE

• 7.1. Overview
• 7.2. Company Market Ranking
• 7.3. Key Development Strategies

8. COMPANY PROFILES

• 8.1. Lonza Group
  • 8.1.1. Overview
  • 8.1.2. Financial Performance
  • 8.1.3. Product Outlook
  • 8.1.4. Key Developments
• 8.2. Wuxi AppTec Co. Ltd.
  • 8.2.1. Overview
  • 8.2.2. Financial Performance
  • 8.2.3. Product Outlook
  • 8.2.4. Key Developments
• 8.3. Catalent Inc
  • 8.3.1. Overview
  • 8.3.2. Financial Performance
  • 8.3.3. Product Outlook
  • 8.3.4. Key Developments
• 8.4. Patheon Inc.
  • 8.4.1. Overview
  • 8.4.2. Financial Performance
  • 8.4.3. Product Outlook
  • 8.4.4. Key Developments
• 8.5. Cambrex
  • 8.5.1. Overview
  • 8.5.2. Financial Performance
  • 8.5.3. Product Outlook
  • 8.5.4. Key Developments
• 8.6. SIEGFRID
  • 8.6.1. Overview
  • 8.6.2. Financial Performance
  • 8.6.3. Product Outlook
  • 8.6.4. Key Developments
• 8.7. WuXi Biologics
  • 8.7.1. Overview
  • 8.7.2. Financial Performance
  • 8.7.3. Product Outlook
  • 8.7.4. Key Developments
• 8.8. Groupe PCAS
  • 8.8.1. Overview
  • 8.8.2. Financial Performance
  • 8.8.3. Product Outlook
  • 8.8.4. Key Developments

9. Appendix

10. Related Reports